SG11201604501TA - Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer - Google Patents
Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancerInfo
- Publication number
- SG11201604501TA SG11201604501TA SG11201604501TA SG11201604501TA SG11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA SG 11201604501T A SG11201604501T A SG 11201604501TA
- Authority
- SG
- Singapore
- Prior art keywords
- estrogen receptor
- treatment
- breast cancer
- locally advanced
- positive breast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913167P | 2013-12-06 | 2013-12-06 | |
| US201461981672P | 2014-04-18 | 2014-04-18 | |
| PCT/IB2014/002679 WO2015082990A1 (en) | 2013-12-06 | 2014-12-05 | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604501TA true SG11201604501TA (en) | 2016-07-28 |
Family
ID=52347358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604501TA SG11201604501TA (en) | 2013-12-06 | 2014-12-05 | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9675586B2 (ko) |
| EP (1) | EP3089747A1 (ko) |
| JP (1) | JP2016540767A (ko) |
| KR (1) | KR20160085915A (ko) |
| CN (1) | CN105916501A (ko) |
| AU (1) | AU2014358850A1 (ko) |
| CA (1) | CA2932106A1 (ko) |
| HK (1) | HK1223557A1 (ko) |
| IL (1) | IL245758A0 (ko) |
| MX (1) | MX2016007282A (ko) |
| SG (1) | SG11201604501TA (ko) |
| WO (1) | WO2015082990A1 (ko) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| EA030128B1 (ru) | 2012-09-26 | 2018-06-29 | Арагон Фармасьютикалз, Инк. | Способ лечения неметастатического кастрационно-резистентного рака простаты |
| US9586952B2 (en) | 2013-03-14 | 2017-03-07 | Genentech, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| SG11201509508YA (en) | 2013-06-19 | 2015-12-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulator and uses thereof |
| EP3116496A1 (en) | 2014-03-13 | 2017-01-18 | F. Hoffmann-La Roche AG | Methods and compositions for modulating estrogen receptor mutants |
| US20180173846A1 (en) * | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| AR101487A1 (es) | 2014-08-11 | 2016-12-21 | Hoffmann La Roche | Formas cristalinas de un modulador de receptor de estrógeno |
| MA53837A (fr) | 2014-12-18 | 2021-11-10 | Hoffmann La Roche | Tetrahydro-pyrido[3,4-b]indoles modulateurs des récepteurs des oestrogènes et leurs utilisations |
| EP3233828B1 (en) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
| JP6768711B2 (ja) | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
| US9975856B2 (en) | 2015-10-07 | 2018-05-22 | Genentech, Inc. | Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid |
| US10519148B2 (en) | 2015-11-12 | 2019-12-31 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| SG11201807708SA (en) | 2016-04-01 | 2018-10-30 | Zeno Royalties & Milestones Llc | Estrogen receptor modulators |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| AU2018287988A1 (en) * | 2017-06-20 | 2019-10-10 | Breast Cancer Now | Methods and medical uses |
| US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| EP3498273A1 (en) * | 2017-12-14 | 2019-06-19 | Universität Wien | Pharmaceutical composition for modulating the response of a gaba-a receptor |
| WO2019211322A1 (en) * | 2018-05-02 | 2019-11-07 | Mithra Pharmaceuticals S.A. | Treatment of advanced estrogen receptor positive breast cancer |
| JP6916969B1 (ja) | 2018-06-21 | 2021-08-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ３−（（１Ｒ，３Ｒ）−１−（２，６−ジフルオロ−４−（（１−（３−フルオロプロピル）アゼチジン−３−イル）アミノ）フェニル）−３−メチル−１，３，４，９−テトラヒドロ−２Ｈ−ピリド［３，４−ｂ］インドール−２−イル）−２，２−ジフルオロプロパン−１−オールの固体形態及び置換されたフェニル又はピリジニル部分を含む縮合三環式化合物を調製するための方法とそれらの使用方法 |
| IL281191B (en) | 2018-09-07 | 2022-07-01 | Sanofi Sa | Salts of methyl 6-(4,2-dichlorophenyl)-5-[4-[(s3)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-9,8-dihydro-h7-benzo[7 ]anolane-2-carboxylate and processes for their preparation |
| WO2020225375A1 (en) * | 2019-05-09 | 2020-11-12 | Sanofi | 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients |
| CN114929696A (zh) | 2019-05-24 | 2022-08-19 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物的晶型及其制备方法和用途 |
| EP3993787A4 (en) | 2019-08-06 | 2023-07-12 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF MUTANTS |
| JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| SG11201405918XA (en) | 2012-03-20 | 2014-10-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| US9586952B2 (en) | 2013-03-14 | 2017-03-07 | Genentech, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
-
2014
- 2014-12-05 EP EP14827261.0A patent/EP3089747A1/en not_active Withdrawn
- 2014-12-05 JP JP2016536557A patent/JP2016540767A/ja active Pending
- 2014-12-05 KR KR1020167017951A patent/KR20160085915A/ko not_active Application Discontinuation
- 2014-12-05 US US14/561,701 patent/US9675586B2/en not_active Expired - Fee Related
- 2014-12-05 CN CN201480066547.XA patent/CN105916501A/zh active Pending
- 2014-12-05 CA CA2932106A patent/CA2932106A1/en not_active Abandoned
- 2014-12-05 MX MX2016007282A patent/MX2016007282A/es unknown
- 2014-12-05 SG SG11201604501TA patent/SG11201604501TA/en unknown
- 2014-12-05 AU AU2014358850A patent/AU2014358850A1/en not_active Abandoned
- 2014-12-05 WO PCT/IB2014/002679 patent/WO2015082990A1/en active Application Filing
-
2016
- 2016-05-22 IL IL245758A patent/IL245758A0/en unknown
- 2016-10-14 HK HK16111865.1A patent/HK1223557A1/zh unknown
-
2017
- 2017-05-08 US US15/589,391 patent/US10034860B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015082990A1 (en) | 2015-06-11 |
| CA2932106A1 (en) | 2015-06-11 |
| AU2014358850A8 (en) | 2016-08-04 |
| IL245758A0 (en) | 2016-07-31 |
| US20150157606A1 (en) | 2015-06-11 |
| AU2014358850A1 (en) | 2016-06-16 |
| EP3089747A1 (en) | 2016-11-09 |
| US10034860B2 (en) | 2018-07-31 |
| HK1223557A1 (zh) | 2017-08-04 |
| WO2015082990A8 (en) | 2016-07-21 |
| MX2016007282A (es) | 2016-09-07 |
| US9675586B2 (en) | 2017-06-13 |
| JP2016540767A (ja) | 2016-12-28 |
| CN105916501A (zh) | 2016-08-31 |
| KR20160085915A (ko) | 2016-07-18 |
| US20170239219A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1223557A1 (zh) | 用於治療局部晚期或轉移性雌激素受體陽性乳腺癌的雌激素受體調節劑 | |
| HUS2400002I1 (hu) | Mellrák kezelése szelektív ösztrogénreceptor-módosítók alkalmazásával | |
| IL237558A0 (en) | Methods for treating locally advanced breast cancer | |
| IL245196A0 (en) | Antibodies against cd38 for the treatment of human cancers | |
| IL245731A0 (en) | Combined treatment for cancer | |
| PT3033086T (pt) | Terapia de combinação para o tratamento de cancro | |
| EP2968343A4 (en) | POLY THERAPY FOR TREATING CANCER | |
| HK1222869A1 (zh) | 用於治療癌症的針對 的偶聯抗體 | |
| HK1219737A1 (zh) | 用於治療癌症的新化合物 | |
| HK1222548A1 (zh) | 治療惡性腫瘤的藥物組合 | |
| HK1213909A1 (zh) | 通過調節 治療乳腺癌 | |
| IL281541A (en) | Specific anti-cd38 antibodies for treating human cancers | |
| HK1223547A1 (zh) | 癌症治療方法 | |
| IL245551A0 (en) | Anti-matriptase antibodies for cancer treatment | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| EP3077812A4 (en) | Methods for the prognosis of breast cancer | |
| GB201321531D0 (en) | Treatment for cancers | |
| AP2015008905A0 (en) | Novel compounds for the treatment of cancer | |
| GB201300546D0 (en) | Cancer Treatment |